Novo Nordisk was once one of the highest-valued healthcare stocks by market capitalization. As a leader in the emerging and rapidly growing weight management drug market, its prospects were once highly regarded by the market. However, due to a series of successive setbacks, its stock price has fallen more than 40% over the past 12 months.
Despite this, the rationale for investing in Novo Nordisk stock remains compelling. First, the company’s recent regulatory progress has been quite strong. In recent weeks, Novo Nordisk has secured key label expansions for some of its products, which will significantly impact its performance. Its most famous weight management drug, Wegovy, has been approved in the United States for treating metabolic dysfunction-associated steatohepatitis (MASH). Obesity is a major risk factor for this disease, which in severe cases can lead to serious liver scarring, affecting millions of patients in the US. Currently, there is only one approved therapy on the market, Rezdiffra, sold by Madrigal Pharmaceuticals, which recorded $350 million in sales in its first fiscal year post-launch, demonstrating strong market demand. Therefore, Wegovy has the potential for great success in this new indication, potentially bringing in over $1 billion in incremental sales. Meanwhile, in Europe, its oral GLP-1 drug Rybelsus has also received an indication expansion to reduce the risk of specific cardiovascular events, including heart attack and stroke, which is also highly significant for the company. The company also expects Wegovy to be approved in Europe for treating multiple sclerosis, and Rybelsus is anticipated to gain approval in the US for cardiovascular disease.
Second, the prospects for Novo Nordisk’s R&D pipeline remain promising. Although R&D setbacks have been a major challenge over the past year, the company still has a pipeline of potential projects. Earlier this year, the company submitted an application to the US Food and Drug Administration for oral semaglutide for weight management. If approved, it would become the first oral GLP-1 drug launched in this field, potentially allowing it to lead the market once again. This opportunity is substantial, as a more flexible, convenient, and potentially cheaper oral formulation is expected to further drive rapid market growth. Simultaneously, the company is preparing regulatory submissions for its next-generation GLP-1 therapy, CagriSema; although its performance in Phase III clinical trials did not fully meet Wall Street expectations, it is still projected to potentially achieve sales of up to $15.2 billion by 2030.
Third, Medicare coverage may be imminent. Reports suggest that the US Centers for Medicare & Medicaid Services is considering including GLP-1 class weight loss drugs in insurance coverage. Although the previous administration rejected a similar proposal, the current administration is considering launching a five-year pilot program that would allow state Medicare plans to cover these drugs. This would enable more patients to access third-party payments, significantly boosting demand for such therapies, especially given the current high price barrier. While the proposal is not yet finalized, given the multiple benefits of these drugs beyond weight loss, federal Medicare coverage is not unimaginable.
In summary, although Novo Nordisk has faced headwinds over the past year, the company continues to make steady progress. Clinical and regulatory milestones are expected to help it launch new products, sustain considerable revenue and profit growth, and the potential expansion of payment coverage will also positively impact its financial performance. Overall, the company’s long-term prospects remain attractive, and the current low stock price may present a good buying opportunity for investors.
